What is HRT used for? Menopause benefits and risks explained

What is HRT used for?

Hormone replacement therapy (HRT) can help manage symptoms associated with perimenopause and menopause, including hot flushes and night sweats. Some forms also help prevent bone loss. The NHS benefits-and-risks guide emphasises that suitability depends on symptoms, age and individual risk factors.

This guide does not promise a percentage improvement or recommend HRT solely to prevent heart disease, diabetes or dementia.

Systemic and local treatment are different

The NHS HRT types guide explains these distinctions. Tablets, patches, gels and sprays have different instructions and risk considerations. Follow the actual product rather than assume all patches share a schedule.

Adding progestogen to systemic oestrogen helps protect the endometrium; it should not be described as eliminating every risk of endometrial cancer. The regimen and adherence matter.

Put risk numbers in context

The NHS patient guide summarises approximately five additional breast-cancer cases per 1,000 women taking combined HRT for five years. That estimate describes the population and exposure in the source; it is not a forecast for every formulation or individual.

Risk depends on the type of HRT, duration, age and baseline health. Oral and transdermal routes have different clot and stroke considerations. A clinician should discuss the relevant evidence and options rather than simply label one route risk-free.

Vaginal oestrogen has its own assessment

The NHS vaginal-oestrogen guide explains that little medicine reaches the wider body with low-dose local treatment, and accompanying progestogen is usually not needed.

Local treatment can be used for continuing symptoms with review. That is not a blanket promise of indefinite safety. NICE menopause recommendations discuss regular review and particular considerations for people with a breast-cancer history, including those receiving cancer treatments.

Medical history and follow-up

Tell the clinician about unexplained vaginal bleeding, cancer history, clot or cardiovascular conditions, liver problems, migraine and all medicines. Unexplained bleeding needs assessment, not automatic treatment as a menopause symptom.

Agree how benefit and adverse effects will be reviewed. HRT is not contraception; discuss a separate pregnancy-prevention plan if needed. Our period-delay guide covers a different indication, not an interchangeable HRT regimen.

Prescrivia is a technology intermediary. Independent clinicians decide suitability; licensed pharmacies dispense where applicable. No hormone treatment, access or outcome is guaranteed.

General information only, not medical advice. Follow the leaflet for your actual product and discuss decisions with a qualified clinician. See the current clinical, legal and language review statuses for this edition.

Sources

• NHS risk summary: benefits and individual factors, combined-HRT breast-cancer estimate over five years and route-dependent clot/stroke risks.
• NHS distinctions among systemic combined/oestrogen-only regimens and local vaginal treatment.
• NHS guidance: low-dose local vaginal oestrogen addresses local symptoms and usually does not need accompanying progestogen.
• NICE menopause recommendations: individual risk discussions, regular review and specialist considerations, including breast-cancer history.

Sources checked online on 6 October 2026. Country-specific guidance does not establish availability or prescribing rules throughout Europe.